Skip to main content
. 2024 Jan 11;80:101880. doi: 10.1016/j.molmet.2024.101880

Figure 6.

Figure 6

ActRII inhibition drives skeletal muscle hypertrophy in the absence of Akt.

A) Experimental schematic.

B) Immunoblot analysis for indicated proteins in control and M-AktDKO mice refed for 1 h following 16 h of fasting.

C) Weights (mg) of TA, EDL, soleus, and gastrocnemius muscles isolated from control and M-AktDKO mice treated for 14 days.

D) Percent difference in weight of TA muscles compared to control group.

E) Percent difference in weight of EDL muscles compared to control group.

F) Percent difference in weight of soleus muscles compared to control group.

G) Percent difference in weight of gastrocnemius muscles compared to control group.

H) Percent increase in muscle weights induced by bimagrumab within genotypes.

n = 5 mice for control and M-AktDKO groups, n = 6 mice for M-AktDKO + bimagrumab group, and n = 7 for control + bimagrumab group.∗p < 0.05, ∗∗p < 0.001, ∗∗∗p < 0.0005, ∗∗∗∗p < 0.0001 for control vs. Control + bimagrumab, M-AktDKO, and M-AktDKO + bimagrumab; #p < 0.05, ##p < 0.001, ###p < 0.0005, ####p < 0.0001 for control + bimagrumab vs. M-AktDKO and M-AktDKO + bimagrumab; & p < 0.05 for M-AktDKO vs. M-AktDKO + bimagrumab.